Arrowhead Research | ARWR - Gross Profit On Sales



Arrowhead Research reported 27.77M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 10.75M 3.11M Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Arrowhead Research 27.77M 514.94M Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
Ligand Pharmaceuticals USD 72.86M 32.38M Jun/2025
Merck USD 12.99B 224M Jun/2025
Moderna USD 18M 1000K Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
TG Therapeutics USD 122.21M 16.9M Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025
Xencor 43.61M 10.88M Jun/2025